Sunday, June 13
Shadow

Louisville metro health systems get doses of new COVID-19 antibody treatment – WLKY Louisville

A new antibody therapy could help reduce the number of COVID-19 patients in Louisville.The University of Louisville Health and Norton Health announced the two health systems have each received more than 100 doses of bamlanivimab, a new treatment approved by the Food and Drug Administration.According to health officials, the monoclonal antibody injection is only for COVID-19 patients who are at higher risk of hospitalization and are early into treatment for the disease.Dr. Jason Smith at UofL Health said the treatment is most effective when administered within a few days of a person testing positive for the virus. The goal is to kick-start an immune response against the infection.Smith stressed the limited availability of the drug before more shipments are sent around the country, including how much is available over the next few weeks.The news that the antibody therapy has made its way to Kentucky comes as the state continues to see the impacts from another significant surge in cases and hospitalizations. Gov. Andy Beshear announced new measures for the state to help curb the spread.Bamlanivimab treatments require a physician’s order. It is also not authorized for patients who are hospitalized or require oxygen therapy due to COVID-19.The antibody therapy is being distributed under an emergency use authorization by the FDA. More research will be conducted as it’s distributed across the country.Click here to read more about bamlanivimab from the FDA.

A new antibody therapy could help reduce the number of COVID-19 patients in Louisville.

The University of Louisville Health and Norton Health announced the two health systems have each received more than 100 doses of bamlanivimab, a new treatment approved by the Food and Drug Administration.

According to health officials, the monoclonal antibody injection is only for COVID-19 patients who are at higher risk of hospitalization and are early into treatment for the disease.

Dr. Jason Smith at UofL Health said the treatment is most effective when administered within a few days of a person testing positive for the virus. The goal is to kick-start an immune response against the infection.

Smith stressed the limited availability of the drug before more shipments are sent around the country, including how much is available over the next few weeks.

The news that the antibody therapy has made its way to Kentucky comes as the state continues to see the impacts from another significant surge in cases and hospitalizations. Gov. Andy Beshear announced new measures for the state to help curb the spread.

Bamlanivimab treatments require a physician’s order. It is also not authorized for patients who are hospitalized or require oxygen therapy due to COVID-19.

The antibody therapy is being distributed under an emergency use authorization by the FDA. More research will be conducted as it’s distributed across the country.

Click here to read more about bamlanivimab from the FDA.

Leave a Reply

Your email address will not be published. Required fields are marked *